Subsequent chemotherapy after anti-PD-1/PD-L1 therapy improved efficacy outcomes in other types of cancers [19–21], which may have contributed to the higher efficacy of the nivolumab combination treatments in the Japanese subpopulation in this study. This evidence concerns the gene PDCD1 and cancer.